ALNY
ALNYLAM PHARMACEUTICALS, INC.
NASDAQ · Healthcare · Biotechnology · US
$239.56
−2.42%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$246.49
From 52W high−51.23%
Volume2.73M
Market cap$32.06B
P/E (TTM)39.3x
P/S (TTM)6.7x
Div yield—
Key dataSep 18, 2026
Open
$246.49
From 52W high
−51.23%
Volume
2.73M
Market cap
$32.06B
ValuationView details →
P/E (Fwd)
28.4x
EV/EBITDA
26.1x
P/E (TTM)
39.3x
RSI (14)
46.8
MomentumView details →
1D Return
−2.42%
YTD Return
−39.15%
SummaryUpdated Jun 1, 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is a pioneering biopharmaceutical company founded in 2002 and headquartered in Cambridge, Massachusetts. The company went public in 2004 and has established itself as a leader in RNA interference (RNAi) therapeutics, a revolutionary approach to treating diseases by silencing specific genes that cause illness. Alnylam has successfully commercialized multiple RNAi-based medicines and maintains a robust pipeline targeting both rare genetic diseases and more prevalent conditions including cardiovascular, metabolic, and neurological disorders.
Similar companies
Latest newsMore news →
AstraZeneca announced on Friday that its Phase 3 clinical trial for an experimental silencer drug in ATTR-CM patients failed to show additional benefit over existing stabilizer therapy, impacting its partnership with Ionis Pharmaceuticals and the broader market.23d agoAlnylam Pharmaceuticals announced it will present new clinical and real-world data across its ATTR and hypertension programs at the ESC Congress 2026 in Munich, Germany, from August 28-31, 2026.27d ago